Timothy J. McDonnell

Bcl-2 Expression In The Prostate And Its Association With Androgen-Independent Prostate Cancer

Timothy J. McDonnell, Patricia Troncoso, Shawn Brisbay, Leland W.K. Chung et autres

Prostate cancer is now the most commonly diagnosed malignancy in American men, surpassing even carcinoma of the lung. Most patients have advanced disease at the time of diagnosis and are, therefore, not considered candidates for potentially curative surgical resection. The most effective …

Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Michelle J. Lee, Kumudha Balakrishnan, Arman Petrosyants, Daniil S. Wiebe et autres

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in the U.S, with well-established differences in clinical presentation and survival among African American (AA) patients compared to non-Hispanic white patients (e.g., Shenoy et al., Cancer, 2011). However, lack …

us (code pays fourni par la source)

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Michelle J. Lee, Kumudha Balakrishnan, Pavel Zemskiy, Timothy J. McDonnell et autres

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma worldwide. Multiple epidemiological studies have evaluated how differences in environmental factors, race and ethnicity impact clinical presentation and outcome in DLBCL, but limited data exist to address differences …

us (code pays fourni par la source)

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Brooj Abro, Matthew J. Maurer, Thomas M. Habermann, Richard Burack et autres

ABSTRACT: Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.

us (code pays fourni par la source)

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan et autres

ABSTRACT: Underrepresentation of racial and ethnic subgroups in cancer clinical trials remains a persistent challenge. Restrictive clinical trial eligibility criteria have been shown to exacerbate this problem. We previously identified that up to 24% of patients treated with standard immunochemotherapy would have …

us (code pays fourni par la source)

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

James R. Cerhan, Matthew J. Maurer, Brian K. Link, Andrew L. Feldman et autres

To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older …

us (code pays fourni par la source)

The Irish national chronic obstructive pulmonary disease quality improvement collaborative: an adaptive learning collaborative

Orla Woods, Rachel MacDonell, John Brennan, Lucia Prihodová et autres

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the the most common disease-specific cause of adult emergency hospital admissions in Ireland. Preliminary groundwork indicated that treatment of acute exacerbations of COPD (AECOPD) in Ireland is not standardised between public hospitals. Applying Institute for …

ie (code pays fourni par la source)

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski et autres

Background: Shorter diagnosis to treatment interval (DTI) has been shown to be associated with more aggressive disease features and inferior outcomes in diffuse large B-cell lymphoma (DLBCL; Maurer et al, JCO 2018). Additional confirmatory studies have also shown that DTI is related …

us (code pays fourni par la source)

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Arushi Khurana, Raphael Mwangi, James R. Cerhan, Jonathon B. Cohen et autres

Background: High Grade B cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements(R) was introduced as an entity in 2016 by the WHO revised 4 th edition. In 2022, both the WHO 5 th edition (beta version) and the International Consensus …

us (code pays fourni par la source)

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Brooj Abro, Matthew J. Maurer, Thomas M. Habermann, Richard Burack et autres

Introduction: The use of standardized, evidence-based classification systems is crucial for the accurate diagnosis and treatment of diseases. Moreover, standardized classification facilitates research and epidemiologic studies and promotes consistency in communication among healthcare professionals. Since 2016, the revised 4 th edition of …

us (code pays fourni par la source)

Supplementary Figures 1-4 from The RB-E2F1 Pathway Regulates Autophagy

Hong Jiang, Vanesa Martı́n, Candelaria Gomez‐Manzano, G. David Johnson et autres

Supplementary Figures 1-4 from The RB-E2F1 Pathway Regulates Autophagy

Supplementary Figures 1-4 from The RB-E2F1 Pathway Regulates Autophagy

Hong Jiang, Vanesa Martı́n, Candelaria Gomez‐Manzano, G. David Johnson et autres

Supplementary Figures 1-4 from The RB-E2F1 Pathway Regulates Autophagy